Greater Risks With Post-TAVR Rivaroxaban Halt GALILEO Trial Greater Risks With Post-TAVR Rivaroxaban Halt GALILEO Trial

The phase 3 trial was stopped prematurely after safety concerns were raised about increased risks for all-cause death, thromboembolic events, and bleeding.Medscape Medical News

Source: Medscape Medical News Headlines - October 10, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news